Current Report Filing (8-k)
November 13 2018 - 12:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 12, 2018
IMPRIMIS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
12264
El Camino Real, Suite 350
|
|
|
San
Diego, CA
|
|
92130
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 704-4040
N/A
(Former name or former address if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01. Other Information.
On
November 12, 2018, Eton Pharmaceuticals, Inc. (“Eton”) issued a press release (the “Eton PR”) reporting
the pricing of its initial public offering of three million six hundred thousand (3,600,000) shares of its common stock at a public
price of $6.00 a share. The Eton PR also stated that Eton’s common stock has been approved for listing on the Nasdaq Global
Market and is expected to begin trading under the ticker symbol “ETON” on November 13, 2018. The proposed offering
is expected to close on November 15, 2018, subject to customary closing conditions. Imprimis Pharmaceuticals, Inc. owns three
million five hundred thousand (3,500,000) shares of Eton common stock.
This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any
sale of Eton securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of such state or jurisdiction.
The
foregoing is only a brief description of the Eton PR, does not purport to be a complete description of the Eton PR and is qualified
in its entirety by reference to the full text of the document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
Item
9.01.
Financial
Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Imprimis
Pharmaceuticals, Inc.
|
|
|
Date:
November 13, 2018
|
By:
|
/s/
Andrew R. Boll
|
|
Name:
|
Andrew R. Boll
|
|
Title:
|
Chief Financial
Officer
|
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Apr 2024 to May 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2023 to May 2024